Could cause temporary or reversible harm; serious harm is unlikely.
CGMP Deviations: FDA analysis detected N-Nitrosodimethylamine (NDMA) impurity above the acceptable intake level
| Brand name | METFORMIN |
| Generic name | METFORMIN ER 500 MG |
| Active ingredient(s) | METFORMIN HYDROCHLORIDE |
| Distributed by / for | Granules Pharmaceutical Inc., Chantilly, VA |
| NDC | 70010-492-01 |
| Full product label | Metformin Hydrochloride Extended-Release Tablets USP, 750 mg, a) 100 ct. bottle (NDC 70010-492-01) and 500 ct. bottle (NDC 70010-492-05), Manufactured for: Granules Pharmaceutical Inc., Chantilly, VA, Manufactured by: Granules India Limited, Hyderabad - 500-081, India |
| Recalling firm | Granules Pharmaceuticals Inc |
| Distribution | US Nationwide |
| Quantity | a) 476,073 bottles; b) 2,100 bottles |
| Recall initiated | 2020-07-03 |
| Report date | 2020-07-22 |
| Recall completed | — |
| Recall number | D-1386-2020 |
| Classification | Class II |
| FDA status | Ongoing |
| Origin on file | Chantilly VA United States |
Source: U.S. FDA enforcement database (openFDA). Look this up on the official FDA recalls site ↗